<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Defactinib - VS 6063 | PF 04554878

產(chǎn)品貨號

Axon 2574 CAS [1073154-85-4] MF C20H21F3N8O3SMW 510.49 Purity: 98% Soluble in DMSO Description Orally available second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (PYK2) with an acceptable safety profile in clinical trials (IC50 values 0.6 nM for each kinase, and >100-fold greater selectivity for FAK and PYK2 than for other, non-target kinases). Structurally closely related to PF 431396 (Axon 2107). KEYWORDS: Defactinib | supplier | FAK/PYK2 inhibitor | VS 6063 | PF 04554878 | PF04554878 | VS6063 | PF4554878 | CAS [1073154-85-4] | [1073160-26-5] | Phosphorylation | FAK | PYK2 | Inhibitor | focal adhesion kinase | proline-rich tyrosine kinase-2 | solid | tumor | malignancies | prostate cancer

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Defactinib - VS 6063 | PF 04554878

Based on 120 reference(s) in Google Scholar 10 10 120

Axon 2574

CAS [1073154-85-4]

MF C20H21F3N8O3S
MW 510.49

Purity: 98%
Soluble in DMSO

Defactinib

Description

Orally available second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (PYK2) with an acceptable safety profile in clinical trials (IC50 values 0.6 nM for each kinase, and >100-fold greater selectivity for FAK and PYK2 than for other, non-target kinases). Structurally closely related to PF 431396 (Axon 2107).

KEYWORDS: Defactinib | supplier | FAK/PYK2 inhibitor | VS 6063 | PF 04554878 | PF04554878 | VS6063 | PF4554878 | CAS [1073154-85-4] | [1073160-26-5] | Phosphorylation | FAK | PYK2 | Inhibitor | focal adhesion kinase | proline-rich tyrosine kinase-2 | solid | tumor | malignancies | prostate cancer

YC Lee et al. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res. 2015 Nov 15;75(22):4949-59.

SF Jones et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015 Oct;33(5):1100-7.

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Cycle Regulation Cell Signaling & Oncology FAK PYK2 Wnt-β-Catenin EC 2.7.10.2 Pfizer Licensed Products

Orally available second generation inhibitor of FAK and PYK2

Chemical name

N-methyl-4-(4-((3-(N-methylmethylsulfonamido)pyrazin-2-yl)methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)benzamide

Parent CAS No.

[1073154-85-4]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>